WO2004060305A2 - Anti-cancer medicaments - Google Patents
Anti-cancer medicaments Download PDFInfo
- Publication number
- WO2004060305A2 WO2004060305A2 PCT/US2003/041425 US0341425W WO2004060305A2 WO 2004060305 A2 WO2004060305 A2 WO 2004060305A2 US 0341425 W US0341425 W US 0341425W WO 2004060305 A2 WO2004060305 A2 WO 2004060305A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- switch control
- formula
- phenyl
- Prior art date
Links
- 0 CCC1*CCC1 Chemical compound CCC1*CCC1 0.000 description 27
- PBRULHUFAUEFBB-UHFFFAOYSA-N CCN(c(ccc(NC(Nc1ccc(CN2CCN(CCS(O)(=O)=O)CC2)cc1)=O)c1)c1N1)C1=O Chemical compound CCN(c(ccc(NC(Nc1ccc(CN2CCN(CCS(O)(=O)=O)CC2)cc1)=O)c1)c1N1)C1=O PBRULHUFAUEFBB-UHFFFAOYSA-N 0.000 description 1
- HPWQEXFHVCWNNA-UHFFFAOYSA-N CCOC(CNS(N(Cc(cc1)ccc1C(OC)=O)C(OC(C)(C)C)=O)(=O)=O)=O Chemical compound CCOC(CNS(N(Cc(cc1)ccc1C(OC)=O)C(OC(C)(C)C)=O)(=O)=O)=O HPWQEXFHVCWNNA-UHFFFAOYSA-N 0.000 description 1
- JVLYJKBKFZYHHJ-UHFFFAOYSA-N CCOC(CNS(NCc(cc1)ccc1C(OC)=O)(=O)=O)=O Chemical compound CCOC(CNS(NCc(cc1)ccc1C(OC)=O)(=O)=O)=O JVLYJKBKFZYHHJ-UHFFFAOYSA-N 0.000 description 1
- TYHFTTXCCNXNKT-UHFFFAOYSA-N CCOP(Cc(cc1)ccc1-c1cc(-c2ncccc2)nc(-c2ncccc2)c1)(OCC)=O Chemical compound CCOP(Cc(cc1)ccc1-c1cc(-c2ncccc2)nc(-c2ncccc2)c1)(OCC)=O TYHFTTXCCNXNKT-UHFFFAOYSA-N 0.000 description 1
- BIEPZVQJKUDYBT-UHFFFAOYSA-N CCOP(Cc(cc1)ccc1-c1ccnc(-c2ncccc2)c1)(OCC)=O Chemical compound CCOP(Cc(cc1)ccc1-c1ccnc(-c2ncccc2)c1)(OCC)=O BIEPZVQJKUDYBT-UHFFFAOYSA-N 0.000 description 1
- UURKSQXMUNUXSI-UHFFFAOYSA-N CCOP(Cc1ccc(C=C)cc1)(OCC)=O Chemical compound CCOP(Cc1ccc(C=C)cc1)(OCC)=O UURKSQXMUNUXSI-UHFFFAOYSA-N 0.000 description 1
- PJXNBWPOHKROES-UHFFFAOYSA-N CCc(cccc1C)c1N(c1ccccc1)c1ccc(C)cc1 Chemical compound CCc(cccc1C)c1N(c1ccccc1)c1ccc(C)cc1 PJXNBWPOHKROES-UHFFFAOYSA-N 0.000 description 1
- QPSRVBZQFBUZMH-UHFFFAOYSA-N CN(C(CN1Cc(cc2)ccc2C(OC)=O)=O)C1=O Chemical compound CN(C(CN1Cc(cc2)ccc2C(OC)=O)=O)C1=O QPSRVBZQFBUZMH-UHFFFAOYSA-N 0.000 description 1
- QFMWOTQEDHEGOK-UHFFFAOYSA-N COC(c1ccc(CNC(NS(N2CCCC2)(=O)=O)=O)cc1)=O Chemical compound COC(c1ccc(CNC(NS(N2CCCC2)(=O)=O)=O)cc1)=O QFMWOTQEDHEGOK-UHFFFAOYSA-N 0.000 description 1
- PSXHNKVPGJFLBT-UHFFFAOYSA-N Cc([o]nc1-c2ccccc2)c1-c1cccc(NC(c(cc2)ccc2C(OC)=O)=O)c1 Chemical compound Cc([o]nc1-c2ccccc2)c1-c1cccc(NC(c(cc2)ccc2C(OC)=O)=O)c1 PSXHNKVPGJFLBT-UHFFFAOYSA-N 0.000 description 1
- NISFTDVOCNLHGK-UHFFFAOYSA-N Cc(ccc(NC(c1ccc(CN(C(C2(O)O)=O)N(C)C2=O)cc1)=O)c1)c1Nc1nc(-c2ccncc2)ccn1 Chemical compound Cc(ccc(NC(c1ccc(CN(C(C2(O)O)=O)N(C)C2=O)cc1)=O)c1)c1Nc1nc(-c2ccncc2)ccn1 NISFTDVOCNLHGK-UHFFFAOYSA-N 0.000 description 1
- DGZFXMDNNJTYSG-UHFFFAOYSA-O Cc(ccc(NC(c1ccc(CN(C(C2([O-])O)=O)[NH+](C)C2=O)cc1)=O)c1)c1Nc1nc(-c2cnccc2)ccn1 Chemical compound Cc(ccc(NC(c1ccc(CN(C(C2([O-])O)=O)[NH+](C)C2=O)cc1)=O)c1)c1Nc1nc(-c2cnccc2)ccn1 DGZFXMDNNJTYSG-UHFFFAOYSA-O 0.000 description 1
- RRIHWQBCRHBNLM-UHFFFAOYSA-N O=C(c1ccccc1-c1ccccc1)Nc(cc1)ccc1NCCc1ccccn1 Chemical compound O=C(c1ccccc1-c1ccccc1)Nc(cc1)ccc1NCCc1ccccn1 RRIHWQBCRHBNLM-UHFFFAOYSA-N 0.000 description 1
- PDZUQMSAGGPFKU-UHFFFAOYSA-N OC(c1cc(NC(c2cccc(NC(Nc(cc3C(F)(F)F)ccc3Cl)=O)c2)=O)ccc1)=O Chemical compound OC(c1cc(NC(c2cccc(NC(Nc(cc3C(F)(F)F)ccc3Cl)=O)c2)=O)ccc1)=O PDZUQMSAGGPFKU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to novel compounds and methods of using those compounds to treat oncological conditions.
- kinases utilize activation loops and kinase domain regulatory pockets to control their state of catalytic activity. This has been recently reviewed (see, e.g., M. Huse and J. Kuriyan, Cell (2002) 109:275).
- the present invention is broadly concerned with new compounds for use in treating anti- inflammatory conditions and methods of treating such conditions.
- the inventive compounds have the formula
- R 1 is selected from the group consisting of aryls (preferably C 6 -C 1S , and more preferably
- each X and Y is individually selected from the group consisting of -O-, -S-, -NR 6 -,
- A is selected from the group consisting of aromatic (preferably C 6 -C 18 , and more preferably C 6 -C ⁇ 2 ), monocycloheterocyclic, and bicycloheterocyclic rings;
- D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrblyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;
- E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
- L is selected from the group consisting of -C(O)-, -S(O) 2 - 5 -N(R 6 )CO-, -N(R 6 )SO 2 -,
- each R 4 group is individually selected from the group consisting of -H, alkyls (preferably
- C,-C I2 and more preferably C r C 6
- aminoalkyls preferably C r C 12 , and more preferably C,-C 6
- alkoxyalkyls preferably C r C 12 , and more preferably C r C 6
- aryls preferably C 6 -C 18 , and more preferably C 6 -C 12
- aralkyls preferably C,-C, 2 , and more preferably C,-C 6
- heterocyclyls and heterocyclylalkyls except when the
- R 4 substituent places a heteroatom on an ⁇ /p/z -carbon directly attached to a ring nitrogen on Q; when two R 4 groups are bonded with the same atom, the two R 4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring; each R 5 is individually selected from the group consisting of -H, alkyls (preferably C r
- each R 8 is individually selected from the group consisting of alkyls (preferably C r C 12 , and more preferably C r C 6 ), aralkyls (preferably C r C 12 , and more preferably C,- C 6 ), heterocyclyls, and heterocyclylalkyls; each R-c, group is individually selected from the group consisting of -H, -F, and alkyls (preferably C ⁇ -C 12 , and more preferably C,-C 6 ) .
- R 9 groups are geminal alkyl groups
- said geminal alkyl groups may be cyclized to form a 3-6 membered ring
- G is selected from the group consisting of -O-, -S-, and -N(R 4 )-
- k is 0 or 1
- each Z is individually selected from the group consisting of -O- and -N(R 4 )-
- each ring of formula (I) optionally includes one or more of R 7 , where R 7 is a noninterfering substituent individually selected from the group consisting of -H, alkyls (preferably C r C 12 , and more preferably C,-C 6 ), aryls (preferably C 6 -C, g , and more preferably C 6 -C 12 ), heterocyclyls, alkylaminos (preferably C,-C 12 , and more preferably C r C 6 ), arylaminos (preferably C 6 -C 18 , and more preferably C 6 -
- cycloalkylaminos preferably C 3 -C 18 , and more preferably C 5 -C 12 and preferably C r C 12 , and more preferably C,-C 6
- heterocyclylaminos hydroxys, alkoxys (preferably -C ⁇ , and more preferably C r C 6 ), aryloxys (preferably C 6 - C ⁇ 8 , and more preferably C 6 -C ⁇ 2 ), alkylthios (preferably C r C 12 , and more preferably C,-C 6 ), arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfmyls (preferably C,-C ]2 , andmore preferably C r C 6 ), alkylsulfonyls (preferably C ⁇ C ⁇ , and more preferably C j -C 6 ), aminosulfonyls, and perfluoroalkyls (preferably C r C
- R120 2 .3- ifluoro; 2,3,6-trifluoro; 2, fluoro, 3-chloro; 2-cl.loro,3-fluoro;
- R121 substituted phenyl; oxazolyl; pyridyl; pyrimidyl; pyrazolyl; imidazolyl
- R17, R18 alkyl
- R19 H, alkyl
- Rl 07 phenyl when Q is Q-16, then the compound of fomiula (I) is not
- R 29 alkyl
- R 30 H, t-Bu, benzoyl when Q is Q-21, then the compound of formula (I) is not
- each W is individually selected from the group consisting of -CH- and -N-;
- biphenyl is not biphenyl, benzoxazolylphenyl, pyridylphenyl or bipyridyl;
- 30 benzoyl, substituted phenylaminocarbonyl
- G is selected from the group consisting of -O-, -S-, and -NR 4 -, k is 0 or 1, and u is 1, 2, 3, or 4, then
- R 110 H, t-Bu
- R ⁇ is selected from the group consisting of 6-5 fused heteroaryls, 6-5 fused heterocyclyls, 5-6 fused heteroaryls, and 5-6 fused heterocyclyls.
- R j is selected from the group consisting of
- each R 2 is individually selected from the group consisting of -H, alkyls (preferably C,-
- each R 3 is individually selected from the group consisting of -H, alkyls (preferably C,- C 12 , and more preferably C,-C 6 ), alkylaminos (preferably C,-C 12 , and more preferably C,-C 6 ), arylaminos (preferably C 6 -C 18 , and more preferably C 6 - C I2 ), cycloalkylaminos (preferably C 3 -C 18 , and more preferably C 5 -C 12 and preferably C,-C 12 , and more preferably - ), heterocyclylaminos, halogens, alkoxys (preferably C r C 12 , and more preferably C r C ), and hydroxys; and each R 3 is individually selected from the group consisting of -H, alkyls (preferably C,- C 12 , and more preferably C,-C 6 ), alkylaminos (preferably C,-C 12 , and more preferably C,-C 6 ), arylaminos (preferably C 6
- A is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrimidyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, mdolyl, mdazolyl, belizimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, benzothienyl, pyrazolylpyrimidinyl, imidazopyrimidinyl, and purinyl.
- the activation state of a kinase is determined by the interaction of switch control ligands and complemental switch control pockets.
- One conformation of the kinase may result from the switch control ligand's interaction with a particular switch control pocket while another conformation may result from the ligand's interaction with a different switch control pocket.
- interaction of the ligand with one pocket, such as the "on" pocket results in the kinase assuming an active conformation wherein the kinase is biologically active.
- an inactive conformation (wherein the kinase is not biologically active) is assumed when the ligand interacts with another of the switch control pockets, such as the "off pocket.
- the switch control pocket can be selected from the group consisting of simple, composite and combined switch control pockets. Interaction between the switch control ligand and the switch control pockets is dynamic and therefore, the ligand is not always interacting with a switch control pocket, hi some instances, the ligand is not in a switch control pocket (such as occurs when the protein is changing from an active conformation to an inactive conformation). Li other instances, such as when the ligand is interacting with the environment surrounding the protein in order to determine with which switch control pocket to interact, the ligand is not in a switch control pocket. Interaction of the ligand with particular switch control pockets is controlled in part by the charge status of the amino acid residues of the switch control ligand.
- the switch control ligand When the ligand is in a neutral charge state, it interacts with one of the switch control pockets and when it is in a charged state, it interacts with the other of the switch control pockets.
- the switch control ligand may have a plurality of OH groups and be in a neutral charge state. This neutral charge state results in a ligand that is more likely to interact with one of the switch control pockets through hydrogen boding between the OH groups and selected residues of the pocket, thereby resulting in whichever protein conformation results from that interaction.
- the conformation of the protein determines the activation state of the protein and can therefore play arole in protein-related diseases, processes, and conditions.
- a metabolic process requires a biologically active protein but the protein' s switch control ligand remains in the switch control pocket (i.e. the "off pocket) that results in a biologically inactive protein, that metabolic process cannot occur at a normal rate.
- the protein's switch control ligand remains in the switch control pocket (i.e. the "on" pocket) that results in the biologically active protein conformation, the disease condition will be worsened.
- selective modulation of the switch control pocket and switch control ligand by the selective administration of a molecule will play an important role in the treatment and control of protein-related diseases, processes, and conditions.
- One aspect of the invention provides a method of modulating the activation state of a kinase, preferably abl or bcr-abl alpha-kinase and including both the consensus wild type sequence and disease polymorphs thereof.
- the activation state is generally selected from an upregulated or downregulated state.
- the method generally comprises the step of contacting the kinase with a molecule having the general formula (I). When such contact occurs, the molecule will bind to a particular switch control pocket and the switch control ligand will have a greater propensity to interact with the other of the switch control pockets (i.e., the unoccupied one) and a lesser propensity to interact with the occupied switch control pocket.
- the protein will have a greater propensity to assume either an active or inactive conformation (and consequently be upregulated or downregulated), depending upon which of the switch control pockets is occupied by the molecule.
- contacting the kinase with a molecule modulates that protein's activation state.
- the molecule can act as an antagonist or an agonist of either switch control pocket.
- the contact between the molecule and the kinase preferably occurs at a region of a switch control pocket of the kinase and more preferably in an interlobe oxyanion pocket of the kinase. hi some instances, the contact between the molecule and the pocket also results in the alteration of the conformation of other adjacent sites and pockets, such as an ATP active site.
- the region of the switch control pocket of the kinase comprises an amino acid residue sequence operable for binding to the Formula I molecule.
- binding can occur between the molecule and a specific region of the switch control pocket with preferred regions including the cc-C helix, the ⁇ -D helix, the catalytic loop, the activation loop, and the C-terminal residues or C-lobe residues (all residues located downstream (toward the C-end) from the Activation loop), and combinations thereof.
- the binding region is the ⁇ -C helix
- one preferred binding sequence in this helix is the sequence NEEFLKEAANM, (SEQ ID NO. 2).
- one preferred binding sequence in this loop is HRDLAARNXL (SEQ ID NO. 3).
- one preferred binding sequence in this loop is a sequence selected from the group consisting of DFGLSRLMT (SEQ ID NO.4), GDTYTAH (SEQ ID NO. 5), and combinations thereof.
- one preferred binding residue is F, found at position 416 relative to the full length sequence (residue 194 in SEQ ID NO. 1).
- molecules which interact with the switch control pocket that normally results in a biologically inactive protein conformation will be selected.
- the propensity of the protein to assume a desired conformation will be modulated by administration of the molecule, hi preferred forms, the molecule will be administered to an individual undergoing treatment for cancer including but not limited to chronic myelogeneous leukemia and stromal gastrointestinal tumors, h such forms, it will be desired to select molecules that interact with the switch control pocket that generally leads to a biologically active protein conformation so that the protein will have the propensity to assume the biologically inactive form and thereby alleviate the condition.
- the molecules of the present invention will be administerable in any conventional form including oral, parenteral, inhalation, and subcutaneous. It is preferred for the administration to .be in the oral form.
- Preferred molecules include the preferred formula (I) compounds discussed above.
- Another aspect of the present invention provides a method of treating cancer comprising the step of administering a molecule having the structure of the fomiula (I) compounds to the individual.
- Such conditions are often the result of an overproduction of the biologically active form of a protein, including kinases.
- a hallmark feature of chronic myelogeneous leukemia involves a reciprocal chromosomal translocation involving human chromosomes 9 and 22. This mutation fuses a segment of the bcr gene upstream of the second exon of the c-abl nonreceptor tyrosine kinase gene. This fusion protein is called bcr-abl.
- the invention discloses and utilizes small molecule inhibitors of bcr-abl kinase.
- These inliibitors contain functionality which enable them to bind to an binding region, preferably an interlobe oxyanion regulator pocket in abl kinase.
- the inliibitors may also contain functionality which bind to the ATP pocket or other kinase amino acid residues taken from the N-lobe or C-lobe of the kinase.
- the administering step generally includes the step of causing said molecule to contact a kinase involved with elevated kinase activity such as that found in cancer.
- a particularly preferred kinase to contact is bcr-abl kinase.
- the contact When the contact is between the molecule and a kinase, the contact preferably occurs in a binding region (preferably an interlobe oxyanion pocket of the kinase) that includes an amino acid residue sequence operable for binding to the Formula I molecule.
- Preferred binding regions of the interlobe oxyanion pocket include the ⁇ -C helix region, the catalytic loop, the activation loop, the C-terminal lobe or residues, and combinations thereof.
- one preferred binding sequence in this helix is the sequence VEEFLKEAAVM (SEQ ID NO. 2).
- VEEFLKEAAVM SEQ ID NO. 2
- HRDLAARNXL SEQ ID NO. 3
- one preferred binding sequence in this loop is a sequence selected from the group consisting of DFGLSRLMT (SEQ ID NO.4), GDTYTAH (SEQ ID NO. 5), and combinations thereof.
- a preferred residue with which to bind in the C- terminal lobe is F.
- Such a method permits treatment of cancer by virtue of the modulation of the activation state of a kinase by contacting the kinase with a molecule that associates with the switch control pocket that normally leads to a biologically active form of the kinase when interacting with the switch control ligand. Because the ligand cannot easily interact with the switch control pocket associated with or occupied by the molecule, the ligand tends to interact with the switch control pocket leading to the biologically inactive form of the protein, with the attendant result of a decrease in the amount of biologically active protein.
- the cancer is selected from the group consisting of chronic mylogeneous leukemia and stromal gastrointestinal tumors.
- the molecules may be administered in any conventional form, with any conventional excipients or ingredients. However, it is preferred to administer the molecule in an oral dosage form.
- Preferred molecules are again selected from the group consisting of the preferred formula (I) compounds as discussed above.
- Figure 1 is a schematic representation of a naturally occurring mammalian protein in accordance with the invention including "on” and “off switch control pockets, a transiently modifiable switch control ligand, and an active ATP site;
- Fig. 2 is a schematic representation of the protein of Fig. 1, wherein the switch control ligand is illustrated in a binding relationship with the off switch control pocket, thereby causing the protein to assume a first biologically downregulated confomiation;
- Fig. 3 is a view similar to that of Fig. 1, but illustrating the switch control ligand in its charged-modified condition wherein the OH groups of certain amino acid residues have been phosphorylated;
- Fig. 4 is a view similar to that of Fig. 2, but depicting the protein wherein the switch control ligand is in a binding relationship with the on switch control pocket, thereby causing the protein to assume a second biologically-active confomiation different than the first conformation of Fig. 2;
- Fig. 4a is an enlarged schematic view illustrating a representative binding between the phosphorylated residues of the switch control ligand, and complemental residues from the on switch control pocket;
- Fig. 5 is a view similar to that of Fig. 1, but illustrating in schematic form possible small molecule compounds in a binding relationship with the on and off switch control pockets;
- Fig. 6 is a schematic view of the protein in a situation where a composite switch control pocket is formed with portions of the switch control ligand and the on switch control pocket, and with a small molecule in binding relationship with the composite pocket;
- Fig. 7 is a schematic view of the protein in a situation where a combined switch control pocket is foraied with portions of the on switch control pocket, the switch control ligand sequence, and the active ATP site, and with a small molecule in binding relationship with the combined switch control pocket.
- the present invention provides a way of rationally developing new small molecule modulators which interact with naturally occurring proteins (e.g., mammalian, and especially human proteins) in order to modulate the activity of the proteins.
- Naturally occurring proteins e.g., mammalian, and especially human proteins
- Novel protein-small molecule adducts are also provided.
- the invention preferably makes use of naturally occurring proteins having a conformational property whereby the proteins change their conformations in vivo with a corresponding change in protein activity.
- a given enzyme protein in one confomiation may be biologically upregulated, while in another confomiation, the same protein may be biologically downregulated.
- the invention preferably makes use of one mechanism of confomiation change utilized by naturally occurring proteins, through the interaction of what are termed "switch control ligands" and "switch control pockets" within the protein.
- switch control ligand means a region or domain within a naturally occurring protein and having one or more amino acid residues therein which are transiently modified in vivo between individual states by biochemical modification, typically phosphorylation, sulfation, acylation or oxidation.
- switch control pocket .means a plurality of contiguous or non-contiguous amino acid residues within a naturally occurring protein and comprising residues capable of binding in vivo with transiently modified residues of a switch control ligand in one of the individual states thereof in order to induce or restrict the conformation of the protein and thereby modulate the biological activity of the protein, and/or which is capable of binding with a non-naturally occurring switch control modulator molecule to induce or restrict a protein confomiation and thereby modulate the biological activity of the protein.
- a protein-modulator adduct in accordance with the invention comprises a naturally occurring protein having a switch control pocket with a non-naturally occurring molecule bound to the protein at the region of said switch control pocket, said molecule serving to at least partially regulate the biological activity of said protein by inducing or restricting the conformation of the protein.
- the protein also has a corresponding switch control ligand, the ligand interacting in vivo with the pocket to regulate the confomiation and biological activity of the protein such that the protein will assume a first conformation and a first biological activity upon the ligand-pocket interaction, and will assume a second, different confomiation and biological activity in the absence of the ligand-pocket interaction.
- a protein 100 is illustrated in schematic form to include an "on" switch control pocket 102, and "off switch control pocket 104, and a switch control ligand 106.
- the schematically depicted protein also includes an ATP active site 108.
- the ligand 106 has three amino acid residues with side chain OH groups 110.
- the off pocket 104 contains corresponding X residues 112 and the on pocket 102 has Z residues 114.
- the protein 100 will change its conformation depending upon the charge status of the OH groups 110 on ligand 106, i.e., when the OH groups are unmodified, a neutral charge is presented, but when these groups are phosphorylated a negative charge is presented.
- Figs. 2-4 The functionality of the pockets 102, 104 and ligand 106 can be understood from a consideration of Figs. 2-4.
- the ligand 106 is shown operatively interacted with the off pocket 104 such that the OH groups 110 interact with the X residues 112 forming a part of the pocket 104.
- Such interaction is primarily by virtue of hydrogen bonding between the OH groups 110 and the residues 112.
- this ligand/pocket interaction causes the protein 100 to assume a confo ⁇ nation different from that seen in Fig. 1 and corresponding to the off or biologically downregulated conformation of the protein.
- Fig. 3 illustrates the situation where the ligand 106 has shifted from the off pocket interaction confomiation of Fig.
- Fig. 4a illustrates that the phosphorylated groups on the ligand 106 are attracted to positively charged residues 114 to achieve an ionic-like stabilizing bond. Note that in the on conformation of Fig. 4, the protein conformation is different than the off confomiation of Fig. 2, and that the ATP active site is available and the protein is functional as a kinase enzyme.
- Figs. 1-4 illustrate a simple situation where the protein exhibits discrete pockets 102 and 104 and ligand 106. However, in many cases a more complex switch control pocket pattern is observed.
- Fig.6 illustrates a situation where an appropriate pocket for small molecule interaction is fomied from amino acid residues taken both from ligand 106 and, for example, from pocket 102. This is temied a "composite switch control pocket" made up of residues from both the ligand 106 and a pocket, and is referred to by the numeral 120.
- a small molecule 122 is illustrated which interacts with the pocket 120 for protein modulation purposes.
- FIG. 7 Another more complex switch pocket is depicted in Fig. 7 wherein the pocket includes residues from on pocket 102, and ATP site 108 to create what is termed a "combined switch control pocket.”
- a combined pocket is referred to as numeral 124 and may also include residues from ligand 106.
- An appropriate small molecule 126 is illustrated with pocket 124 for protein modulation purposes.
- Amine 8 is prepared by palladium(O) catalyzed amination of 9, wherein Q is a group capable of oxidative insertion into palladium(O), according to methodology reported by S. Bucliwald. See M.
- R- t is a readily removable protecting group
- Intemiediates 12 wherein p is 1 are readily available or are prepared by reaction of 19 with carbamates 10 under palladium (O)-catalyzed conditions.
- Mi is a group which oxidatively inserts palladium(O) over group M.
- Mi is preferably iodo or bromo.
- Compounds 19 are either commercially available or prepared by one of ordinary skill in the art. Scheme 2.3
- pyridine 46 is alkylated under standard conditions (K 2 C0 3 , DMF, j-I or Mitsunobu conditions employing R 4 -OH) to give pyridine derivative 47.
- N-alkylation with K 2 C0 3 , DMF, R-rl affords pyridones of formula 48.
- Intemiediate 48 is partitioned to undergo a Heck reaction, giving 1-49; a Bucliwald amination reaction, giving 1-51; or a Bucliwald Cu(I) catalyzed O-arylation reaction, to give 1-52.
- the Heck reaction product 1-49 may be optionally hydrogenated to afford the saturated compound 1-50.
- the phenyl ether R ⁇ is methyl
- compounds of fomiula 1-49, 1-50, 1-51, or 1-52 are treated with boron tribromide or lithium chloride to afford compounds of Formula 1-53, wherein R-t is hydrogen.
- Intemiediate 56 wherein M is a suitable leaving group, preferably bromine or chlorine, is partitioned to undergo a Heck reaction, giving 1-57;- a Buchwald amination 0 reaction , giving 1-59; or a Buchwald Cu(I) catalyzed O-arylation reaction, to give 1-60.
- the Heck reaction product 1-57 may be optionally hydrogenated to afford the saturated compound 1-58.
- the phenyl ether R4 is methyl
- compounds of formula 1-57, 1-58, 1-59, or 1-60 are treated with boron tribromide or lithium chloride to afford compounds of Fomiula 1-61, wherein is hydrogen. 5 Scheme 10
- Scheme 12 illustrates the further synthetic elaboration of intermediates 67.
- Removal of the silyl protecting group (TBS) is accomplished by treatment of 67 with flouride (tetra-n- butylammonium fluoride or cesium flouride) to give primary alcohols 68.
- Reaction of 68 with isocyanates 2 gives rise to compounds of Formula 1-69.
- reaction of 68 with [R 6 0 2 C(NH)p]q-E-M, wherein M is a suitable leaving group affords compounds of Fomiula 1-70.
- Oxidation of 68 using the Dess-Martin periodinane D. Dess, J. Martin, J. Am. Chem. Soc.
- aldehydes 71 Reductive amination of 71 with amines 8 gives rise to compounds of Formula 1-72.
- aldehydes 71 may be reacted with ammonium acetate under reductive alkylation conditions to give rise to the primary amine 73.
- Reaction of 73 with isocyanates 2 affords compounds of Formula 1-74.
- Dihydropyrimidinedione 78 may optionally be further substituted by Mitsunobu reaction with alcohols R;OH to give rise to compounds 79.
- Compounds of Formulae 1-81, 1-82, 1-84, and 1-86 are prepared as shown in Scheme 14 by analogy to the sequence previously described in Scheme 12.
- Aminoesters 100 are subjected to reductive alkylation conditions to give rise to intemiediates 101. Condensation of amines 101 with carboxylic acids using an acid activating reagent such as dicyclohexylcarbodiimide (DCC)/hydroxybenzotriazole (HOBt) affords intemiediate amides 102. Cyclization of amides 102 to tetramic acids 104 is 0 ⁇ mediated by Amberlyst A-26 hydroxide resin after trapping of the in situ generated alkoxide 103 and submitting 103 to an acetic acid-mediated resin-release. 104
- DCC dicyclohexylcarbodiimide
- HOBt hydroxybenzotriazole
- M' is t-BuOCH 2 -, BOCNH(CH 2 ) 3 - , BOCNH(CH 2 ) 4 -, HC ⁇ C-CH 2 "
- Scheme 17.2 illustrates the synthetic sequences for converting inte ⁇ nediates 104 to compounds of Formula I.
- Reaction of amines 104.2 and 104.3 with 26 under Buchwald palladium(O) catalyzed amination conditions affords compounds of Fomiulae 1-105.2 and 1-105.3.
- Reaction of acetylene 104.4 with 26 under Sonogashira coupling conditions affords compounds of Fomiula 1-105.4.
- Compounds 1-105.4 may optionally be reduced to the corresponding saturated analogs t; 105.5 by standard hydrogenation.
- Scheme 19.2 illustrates the conversion of intermediates 113 into compounds of Formula 1-115, 1-118, or 117.
- Treatment of 113 with aqueous copper oxide or an alkaline hydroxide affords compounds of Fomiula 1-115.
- treatment of 113 with t- butylmercaptan under copper(I) catalysis in the presence of ethylene glycol and potassium carbonate gives rise to 116 (see 7.Y. Kwong and S. L. Buchwald, Organic Letters (2002) 4:3517.
- Treatment of the t-butyl sulfide ⁇ 6 with acid affords the desired thiols of Fomiula 1-118.
- 113 may be treated with excess ammonia under pressurized conditions to afford compound 117.
- Scheme 19.3 illustrates the conversion of intemiediate 114 into compounds of Fomiula 1-119, 1-122, and 121, by analogy to the sequence described in Scheme 19.2.
- intermediates 133 are reacted with alkenes under palladium(0)-catalyzed Heck reaction conditions to give compounds of Fomiula 1-136.
- Compounds 1-136 are optionally reduced to the corresponding saturated analogs 1-137 by standard hydrogenation conditions or by the action of diimide.
- amines 134c are available via the reduction of amides 134b as shown in Scheme 21.2
- the morpholine amide analogues 134d and morpholine analogues 134e are also available as shown in Scheme 21.2
- Intemiediate 145 is converted to the diesters 148 by reaction with an alkyl iodide in the presence of base, preferably potassium carbonate.
- Intermediates 146-148 are treated with HCl/dioxane to give the secondary amines 149-151, which are then condensed with acids 152 in the presence of PyBOP and di- isopropylethylamine to give compounds of Fomiula 1-153.
- Compounds 1-163 or 1-164 are converted to the desired phosphonates 1-165 by an Arbuzov reaction sequence involving reduction of the esters to benzylic alcohols, conversion of the alcohols to the benzylic bromides, and treatment of the bromides with a tri-alkylphosphite.
- phosphonates 1-165 are converted to the fluorinated analogs 1-166 by treatment with diethylaminosulfur trifluoride (DAST).
- DAST diethylaminosulfur trifluoride
- Scheme 28.2 illustrates the conversion of intemiediate t-butylsulfides 172-175 to the
- a hybrid bcr-abl kinase inhibitor is prepared which also contains an ATP -pocket binding moiety or an allosteric pocket binding moiety Ri-X-A-D.
- the synthesis of moieties Rj-X-A-D are conducted as shown in Scheme 29.
- Readily available intemiediates 177, which contain a group M capable of oxidative addition to palladium(O), are reacted with amines 178 (X NH) under Buchwald Pd(0) amination conditions to afford 179.
- amines or alcohols 178 NH or O
- p 0, the esters 179 are converted to the acids 181 preferably under acidic conditions when Rg is t-butyl.
- Scheme 30 Another sequence for preparing amines or alcohols 180 is illustrated in Scheme 30.
- Compounds of Formula 1-184 are prepared as illustrated in previous schemes 1.1, 2.1, 2.2, 3, 4, 5, 6, 7.1, 7.2, 8, 9, 10, 12, 14, 16.2, 17.2, 18, 19.1, 19.2, 19.3, 20, 21, 22, 23, 24, 25, 26, 27, or 28.2.
- inhibitors of Fomiula I which contain an amide linkage -CO-NH- connecting the oxyanion pocket binding moieties and the Ri-X-A-D moieties are shown in Scheme 32.
- Treatment of acids 181 with an activating agent, preferably PyBOP in the presence of di-iso-propylethylamine, and amines 1-185 gives compounds of Formula I.
- an activating agent preferably PyBOP in the presence of di-iso-propylethylamine
- amines 1-185 gives compounds of Formula I.
- retroamides of Fo ⁇ nula I are fomied by treatment of acids 1-186 with PyBOP in the presence of di-iso-propylethylamine and amines 180.
- hybrid inhibitors possessing oxyanion pocket-binding moiety Q and moiety R,-X-A-(NH)p-D
- hybrid inhibitors possessing oxyanion pocket-binding moiety Q and moiety R X-A-(NH)p-D
- inhibitors of Fomiula I which contain an urea linkage NH-CO-NH- connecting the oxyanion pocket binding moieties and the Ri-X-A-D moieties are prepared as shown in Scheme 34.
- Treatment of amines 180 with p-nitrophenyl chlorofomiate and base affords carbamates 188.
- Reaction of 188 with amines 1-185 gives ureas of Formula I.
- hybrid inhibitors possessing oxyanion pocket-binding moiety Q and moiety R r X-A-(NH)p-D
- a continuous spectrophotometric kinase assay is used, wherein the production of adenosine diphosphate is coupled to the oxidation of NADH and measured as a reduction in absorbance at 340nM.
- Activity of nonphosphorylated Abl kinase was determined by following the production of ADP from the kinase reaction through coupling with the pymvate kinase/lactate dehydrogenase system (e.g., Schindler, et al. Science (2000) 289, 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A 3 o nm ) was continuous measured spectrophometrically. The reaction mixture (200 ⁇ l) contained Abl kinase (3.7 nM.
- IC 50 value was calculated from a series of % inhibition values determined at a range of concentrations of the inhibitor using Prism.
- the IC50 values for Gleveec and PD 180970 were found to be 76 and 24 nM, respectively, which are close to that reported (Schindler, et al. Science (2000) 289, 1938-1942).
- Example A A solution of Example A (60 mg, 0.18 mmol) in THF (10 mL) was added to 3N LiOH (10 mL) at RT, sti ⁇ ed overnight, acidified with 1 N HCl, and extracted with EtOAc. The organic layer was dried (Na 2 S0 ) and concentrated to yield pyrolidine carboxamide, N-[(4- carboxybenzyl)amino]sulfonyl (40 mg, 70% yield).
- Example D To a solution of Example D (8.5g, 30 mmol) in MeOH (80 mL) was slowly added solid NaBEI- 4 (3.42g, 90 mmol) while the reaction temperature was controlled below 20 °C. After stirring for 2h, the reaction was quenched with H 2 0, extracted with EtO Ac (3x100 mL) and the combined organic layers were washed with brine, dried (Na 2 SO 4 ), concentrated in vacuo. The residue was purified via flash column chromatography to yield methyl 4-(((t- butoxycarbonyl)methylamino)methyl)benzoate (6.55g, 77% yield).
- Example E 5.1g, 18 mmol in THF (80 mL) was added K 2 C0 3 (4.2g, 30 mmol) and methyl-carbamic acid 4-nitro-phenyl ester (3.6g, 18 mmol). After being sthred overnight, the resulting solid was filtered. After adding H 2 0 and EtOAc to the filtrate, the organic layer was separated and the aqueous layer was extracted with EtOAc (3x100 mL). The combined organic layers were washed with brine, dried (Na 2 S0 4 ), concentrated in vacuo and purified by flash chromatography to yield Example F (4.4g, 73%).
- Example F (1.85g, 5.5 mmol) in THF (50 mL). After stirring for 2h, the resulting solid was filtered. After adding water and EtOAc to the filtrate, the organic layer was separated and the aqueous layer was extracted with EtOAc (3x100 mL). The combined organic layers were washed with brine, dried (Na 2 S0 ), and concentrated in vacuo to yield methyl 4-((3-methyl-2,4-dioxoimidazolidin-l-yl)methyl)benzoate (1.3g, 90%).
- Example G To the solution of Example G (900 mg, 3.44 mmol) in MeOH (30 mL) was added cone. HCl (10 mL). The resulting solution was heated to reflux for lh, quenched with saturated Na 2 C0 3 (100 mL), and extracted with CH 2 C1 2 (100 mL). After separation, the organic layer was washed with brine, dried (Na 2 S0 ), and concentrated in vacuo to yield 4- ((3-methyl-2,4-dioxoimidazolidin-l-yl)methyl)benzoic acid as a yellow solid. The cmde product was used without further purification.
- Example H 200 mg, 0.81 mmol
- DMF dimethyl methyl sulfoxide
- EDCI 200 mg, 1.0 mmol
- HOBt 150 mg, 1.5mmol
- NMM 0.5 mL
- Reagent BB 300 mg, 1.5 mmol
- the solvent was removed under vacuum.
- the resulting residue was purified by preparative HPLC to yield pure 4-((3-methyl-2,4- dioxoimidazolidin-l-yl)methyl)-N-(4-methyl-3-(pyrimidin-2-ylamino)phenyl)benzamide (20 mg).
- Example I To a solution of Example I (0.73g, 1.84 mmol) in MeOH (30 mL) was added 10% Pd C (200 mg). The reaction mixtare was then stirred at ambient temperatare under 1 atmosphere of H 2 for 45 min. The reaction mixtare was filtered, the solid washed with EtOH, and the combined organics concentrated in vacuo to yield 4- (bis((methylcarbamoyl)methyl)carbamoyl)benzoic acid (0.52g, 92% yield).
- Example 1 The title compound was synthesized following the procedure for the preparation of Example 1 utilizing Example J and Reagent BB to yield N ,N - bis((methylcarbamoyl)methyl)-N 4 -(4-methyl-3-(pyrimidin-2- ylamino)phenyl)terephthalamide.
- Example 1 The title compound was synthesized following the procedure for the preparation of Example 1 utilizing Example j and Reagent AA to yield N*,N - bis((methylcarbamoyl)methyl)-N 4 -(3-(4-phenylpyrimidin-2-ylamino)-4- methylphenyl)terephthalamide.
- Example K 410 mg, 0.99 mmol
- 1,4-dioxane 40 mL
- SOCl 2 650 mg, 5.50 mmol
- the solvent and excessive SOCl 2 was removed in vacuo to yield N-(3-(4-phenylpyrimidin-2-ylamino)-4- methylphenyl)-4-(chloromethyl)benzamide as a yellow solid (460 mg), which was used without further purification.
- Example M 400 mg, 2.06 mmol
- THF 1:1
- NaH 165 mg, 4.24 mmol
- Example L 300 mg, 0.70 mmol
- the solution was heated to 40 °C, stined for 3h and quenched with AcOH (0.5 mL).
- Example O To a solution of Example O (5.5 g, 118 mmol) in solvent of MeOH (50 mL) and
- a NaOMe solution was prepared by adding NaH (60%, dispersion in mineral oil, 43.5 mg, 1.1 mmol) to MeOH (30 mL).
- Example P 300 mg, 0.9 mmol was added to the NaOMe- MeOH solution and the reaction was stirred at RT overnight. The solution was concentrated in vacuo and the residue was dissolved in H 2 0 (30 mL). The aqueous solution was acidified with 3N HCl and the precipitate was filtered and collected to yield methyl 4-(l,l,4-trioxo- [l,2,5]thiadiazolidin-2-ylmethyl)-benzoate (120 mg, 40% yield).
- Example Q (100 mg, 0.35 mmol) in THF (4 mL) and 1.5 mL of 2N aq. LiOH solution was stined at RT for 3h. The solvent was removed under reduced pressure and the residue was dissolved in H 2 0 (20 mL) and acidified with aqueous 3N HCl. The precipitate was filtered and collected to yield 4-(l,l,4-trioxo-[l,2,5]thiadiazolidin-2-ylmethyl)-benzoic acid
- Example S The solution of Example S (3g, 7m mol) in 2N HCl/dioxane 1,4-dioxane (60 mL) was heated to 50°C for 15 min. Then the solvent was removed under reduced pressure to yield ethyl-[N-(N -benzonic methyl ester)-sulfamoyl]-glycinate as a white solid (2g, 86.9% yield).
- Example T A solution of Example T (lg, 30.3 mmol) and NaH (0.32g, 78.7m mol) in THF (120 mL) was heated to reflux for 8h. The mixtare was cooled to RT, then quenched with IN aq. HCl (100 mL) and extracted with CH 2 C1 2 (3 x 100 mL). The combined organic layers were dried (Na 2 S0 ), and concentrated in vacuo and purified by flash chromatography to yield 4- (l,l,3-trioxo-[l,2,5]thiadiazolidin-2-ylmethyl)-benzoic acid methyl ester as a white powder (200mg, 23% yield).
- Example U (200mg, 0.8m mol) in THF (3 mL) and 2N aq. LiOH (1.5 mL) was stined at RT for 3h. The solvent was removed under reduced pressure, and the aqueous layer was acidified with 3N aq. HCl solution to yield 4-(l,l,3-trioxo6-[l,2,5]thiadiazolidin-2- ylmethyl)-benzoic acid a white powder (120 mg, 63%).
- ⁇ -NMR (DMSO-d): 7.90 (d, J 8.4
- Example 13 The title compound was prepared following the procedure of Example 13 utilizing Example W and Example AA to yield 4-(((4,4-dioxothiomo ⁇ holinomethyl)l)methyl)-N-(4- methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl)benzamide.
- Example 13 The title compound was prepared following the procedure of Example 13 utilizing Example W and Example HH to yield 4-(((4,4-dioxothiomo ⁇ holinomethyl)l)methyl)-N-(4- methyl-3-(4-mo ⁇ holinopyrimidin-2-ylamino)phenyl)benzamide.
- Example Z (l.Og, 0.0038 mol) and lithium hydroxide (0.950g) in MeOH (10 mL) was stined at RT for overnight.
- the combined organic layers were washed with H 2 0, dried (MgS0 4 ) and concentrated in vacuo to yield 4-((l-methyl-3,5-dioxo-l,2,4-triazolidin-4- yl)methyl)benzoic acid (0.6 g, 64%).
- Example BB 5.5 g, 118 mmol
- MeOH 50 mL
- EtOAc 50 mL
- 10% Pd/C 0.8 g
- the solvent was removed to yield Example CC (3.4 g, 85%) as a white solid.
- a NaOMe solution was first prepared by adding NaH (60%, dispersion in mineral oil,
- Example CC (300 mg, 0.9 mmol) was added to the NaOMe-MeOH solution and the reaction was stined at RT overnight. The solution was concentrated to dryness in vacuum and the residue was dissolved in H 2 0 (30 mL). The aqueous solution was acidified with 3 N HCl (aq. ) and the result precipitate was filtered and collected to yield Example DD (120 mg, 40% yield).
- Example DD 100 mg, 0.35 mmol
- THF 4 mL
- 2 N aq. LiOH solution was stined at RT for 3h. Then the solvent was removed under reduced pressure and the residue was dissolved in water (20 mL) and acidified with aqueous 3 N HCl. The result precipitate was filtered to yield Example EE (85 mg).
- Example FF (3g, 7m mol) in 2N HCl/dioxane 1,4-dioxane (60 mL) was heated to 50°C for 15 min. The solvent was removedin vacuo to yield Example GG as a white solid (2g, 86.9% yield).
- Example GG (lg, 30.3 mmol) and NaH (0.32g, 78.7m mol) in THF (120 mL) was heated to reflux for 8h. The mixture was cool to RT, quenched with IN aq. HCl solution (100 mL) and extracted with CH 2 C1 2 (3x100 mL). The combined organic phases were dried (Na 2 S0 4 ), and concentrated in vacuo and purified by flash chromatography to yield Example HH as a white powder (200mg, 23% yield).
- Example HH (200mg, 0.8m mol) was dissolved in THF (3 mL), and 1.5 mL solution of 2N aq. LiOH was added to the reaction solution. The mixtare was stirred at RT for 3h. The solvent was removed in vacuo, and the aqueous layer was acidified with 3N aq. HCl solution, and filtered to yield Example II as a white powder (120mg, 63%>).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03814980A EP1590344A4 (en) | 2002-12-31 | 2003-12-26 | Anti-cancer medicaments |
AU2003303639A AU2003303639A1 (en) | 2002-12-31 | 2003-12-26 | Anti-cancer medicaments |
MXPA05007237A MXPA05007237A (en) | 2002-12-31 | 2003-12-26 | Anti-cancer medicaments. |
BR0317863-3A BR0317863A (en) | 2002-12-31 | 2003-12-26 | Anticancer Drugs |
JP2005508623A JP2006519765A (en) | 2002-12-31 | 2003-12-26 | Anticancer drug |
CA002511840A CA2511840A1 (en) | 2002-12-31 | 2003-12-26 | Anti-cancer medicaments |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43730402P | 2002-12-31 | 2002-12-31 | |
US43740302P | 2002-12-31 | 2002-12-31 | |
US43748702P | 2002-12-31 | 2002-12-31 | |
US43741502P | 2002-12-31 | 2002-12-31 | |
US60/437,487 | 2002-12-31 | ||
US60/437,304 | 2002-12-31 | ||
US60/437,403 | 2002-12-31 | ||
US60/437,415 | 2002-12-31 | ||
US46380403P | 2003-04-18 | 2003-04-18 | |
US60/463,804 | 2003-04-18 | ||
US10/746,460 US7144911B2 (en) | 2002-12-31 | 2003-12-24 | Anti-inflammatory medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004060305A2 true WO2004060305A2 (en) | 2004-07-22 |
WO2004060305A3 WO2004060305A3 (en) | 2005-02-10 |
Family
ID=32719725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041449 WO2004060306A2 (en) | 2002-12-31 | 2003-12-26 | Anti-inflammatory medicaments |
PCT/US2003/041425 WO2004060305A2 (en) | 2002-12-31 | 2003-12-26 | Anti-cancer medicaments |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041449 WO2004060306A2 (en) | 2002-12-31 | 2003-12-26 | Anti-inflammatory medicaments |
Country Status (9)
Country | Link |
---|---|
US (7) | US7144911B2 (en) |
EP (2) | EP1590344A4 (en) |
JP (1) | JP2006514691A (en) |
AU (1) | AU2003303641A1 (en) |
BR (1) | BR0317872A (en) |
CA (1) | CA2513627A1 (en) |
MX (1) | MXPA05007236A (en) |
TW (1) | TW200427672A (en) |
WO (2) | WO2004060306A2 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
JP2006527230A (en) * | 2003-06-13 | 2006-11-30 | ノバルティス アクチエンゲゼルシャフト | 2-Aminopyrimidine derivatives as RAF kinase inhibitors |
WO2009046784A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
US7589116B2 (en) | 2003-04-03 | 2009-09-15 | Merck & Co. Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2152079A1 (en) * | 2007-06-04 | 2010-02-17 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
JP2010506850A (en) * | 2006-10-11 | 2010-03-04 | デシフェラ ファーマシューティカルズ,エルエルシー | Kinase inhibitors useful for the treatment of chronic myeloproliferative disorders and other proliferative disorders |
US7741479B2 (en) | 2004-12-07 | 2010-06-22 | Locus Pharmaceuticals, Inc. | Urea inhibitors of MAP kinases |
EP2166858A4 (en) * | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | Novel heterocycle compounds and uses thereof |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
US9562055B2 (en) | 2011-05-13 | 2017-02-07 | Array Biopharma Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9896435B2 (en) | 2012-11-13 | 2018-02-20 | Array Biopharma Inc. | N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
CN108203450A (en) * | 2016-12-19 | 2018-06-26 | 南京工业大学 | A kind of preparation method and application of the compound of arylpyrazoles containing amido phosphonate |
US10351575B2 (en) | 2012-11-13 | 2019-07-16 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
US10683293B2 (en) | 2014-08-04 | 2020-06-16 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10835533B2 (en) | 2014-05-15 | 2020-11-17 | Array Biopharma Inc. | 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor |
US10966966B2 (en) | 2019-08-12 | 2021-04-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11185535B2 (en) | 2019-12-30 | 2021-11-30 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
US11266635B2 (en) | 2019-08-12 | 2022-03-08 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11395818B2 (en) | 2019-12-30 | 2022-07-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US20080045531A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
EP1594847A2 (en) * | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
KR100854211B1 (en) * | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | Novel oxazolidinone derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same for antibiotics |
WO2005080346A1 (en) * | 2004-02-12 | 2005-09-01 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
ATE485300T1 (en) | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | THIENOPYRIMIDINES USABLE AS AURORA KINASE INHIBITORS |
EP1831228A1 (en) * | 2004-12-20 | 2007-09-12 | AstraZeneca AB | Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors |
CA2592118C (en) * | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
CA2592116A1 (en) * | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
EA015252B1 (en) | 2005-05-10 | 2011-06-30 | Интермьюн, Инк. | Method of modulating stress-activated protein kinase system |
WO2006137421A1 (en) * | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent for topical administration |
EP1991544B1 (en) * | 2006-01-30 | 2018-08-15 | vTv Therapeutics LLC | Substituted imidazole derivatives and their use as ptpase inhibitors |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20110189167A1 (en) * | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
US8143293B2 (en) * | 2007-04-20 | 2012-03-27 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases |
WO2009042565A2 (en) * | 2007-09-26 | 2009-04-02 | The University Of North Carolina At Chapel Hill | Inhibitors of eppin/semenogelin binding as male contraceptives |
US20110166132A1 (en) * | 2007-12-13 | 2011-07-07 | Amgen Inc. | Gamma Secretase Modulators |
CN102099036B (en) * | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | Compounds and methods for treating inflammatory and fibrotic disorders |
PE20110598A1 (en) | 2008-10-02 | 2011-08-31 | Respivert Ltd | INHIBITORS OF MITOGEN P38 ACTIVATED PROTEIN KINASE ENZYMES |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
CN102177156B (en) * | 2008-10-10 | 2016-08-24 | 默沙东公司 | Prepare the method for (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and the composition containing (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides |
MX2011004535A (en) * | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities. |
JP5670912B2 (en) * | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | p38 MAP kinase inhibitor |
PE20120585A1 (en) | 2009-02-03 | 2012-06-13 | Trius Therapeutics | CRYSTALLINE FORM OF DIHYDROGEN PHOSPHATE R) -3- (4- (2- (2-METHYLTETRAZOLE-5-IL) PYRIDIN-5-IL) -3-FLUOROFENSIL) -5-HYDROXIMETHYL OXAZOLIDIN-2-ONA |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
US8580767B2 (en) * | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
PT2841428T (en) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Dna-pk inhibitors |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
LT3424920T (en) | 2013-10-17 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2`-methyl-[4,5`-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
KR20230107407A (en) | 2016-06-16 | 2023-07-14 | 데날리 테라퓨틱스 인크. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
KR20190062485A (en) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Methods of treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CA3124112A1 (en) | 2018-12-28 | 2020-07-02 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitors for use in treating cancer |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (en) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
CN114072397A (en) | 2019-05-10 | 2022-02-18 | 德西费拉制药有限责任公司 | Heteroaryl aminopyrimidine amide autophagy inhibitors and methods of use thereof |
LT3966207T (en) | 2019-05-10 | 2023-12-11 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
MA56191A (en) | 2019-06-17 | 2022-04-20 | Deciphera Pharmaceuticals Llc | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF |
CN116348458A (en) | 2019-08-14 | 2023-06-27 | 因赛特公司 | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors |
CN112574201A (en) * | 2019-09-29 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | Arylamine compound, pharmaceutical composition containing arylamine compound, and preparation method and application of arylamine compound |
BR112022006977A2 (en) | 2019-10-11 | 2022-09-20 | Incyte Corp | BICYCLIC AMINES AS CDK2 INHIBITORS |
EP4082614A4 (en) * | 2019-12-27 | 2024-01-24 | Japan Tobacco Inc | Acylsulfamide compound and pharmaceutical use therefor |
AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
US6441005B1 (en) * | 1999-07-28 | 2002-08-27 | Pharmacia & Upjohn Company | Oxazolidinone compounds and compositions, and methods of using the same |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US181411A (en) * | 1876-08-22 | Improvement in frame-squaring tools | ||
US8898A (en) * | 1852-04-20 | Improved device for casting circle-plates, roses | ||
US186221A (en) * | 1877-01-16 | Improvement in time-locks | ||
DE1115350B (en) | 1959-04-17 | 1961-10-19 | Siemens Ag | Circuit breaker, in particular line circuit breaker, with a drive mechanism consisting of a knee joint for the switching element |
GB971307A (en) | 1961-03-02 | 1964-09-30 | Wellcome Found | 5-anilinopyrimidines |
DE1670701A1 (en) | 1966-05-23 | 1970-11-12 | Bayer Ag | Process for the preparation of thiaimidazolidines |
GB1127875A (en) | 1967-03-23 | 1968-09-18 | Parke Davis & Co | 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils |
DE2156343A1 (en) | 1970-11-13 | 1972-05-18 | Ici Ltd | Heat-stable aromatic polymers - containing sulphone -or oxo-groups |
US3818024A (en) * | 1972-02-16 | 1974-06-18 | Velsicol Chemical Corp | Benzothiazol substituted thiadiazolidines |
CH565887A5 (en) | 1972-08-22 | 1975-08-29 | Ciba Geigy Ag | |
US3939122A (en) * | 1973-04-11 | 1976-02-17 | Bayer Aktiengesellschaft | Process for the preparation of compounds which contain hydantoin rings |
FR2337554A1 (en) | 1976-01-08 | 1977-08-05 | Buzas Andre | (1)-Substd. (2)-phenyl-(4)-butyl-pyrazolidine dione salts - analgesics and antiinflammatories with little ulcerogenic action |
US4093624A (en) * | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
FR2396549A2 (en) | 1977-07-06 | 1979-02-02 | Buzas Andre | Antiinflammatory pyrazolidine-di:one cpds. - with reduced ulcerogenic activity |
DE2856955C2 (en) | 1977-08-02 | 1986-01-09 | Western Electric Co., Inc., New York, N.Y. | Method and device for digital-to-analog and analog-to-digital conversion |
US4256758A (en) | 1979-06-11 | 1981-03-17 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
US4298743A (en) | 1979-09-11 | 1981-11-03 | Merck & Co., Inc. | 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
US4296237A (en) * | 1979-09-11 | 1981-10-20 | Merck & Co., Inc. | 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones |
US4432992A (en) * | 1979-11-05 | 1984-02-21 | Merck & Co., Inc. | 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
US4366189A (en) | 1979-12-21 | 1982-12-28 | Ciba-Geigy Corporation | 4-Heterocyclyl-4'-vinylstilbenes |
JPS5915247A (en) | 1982-07-16 | 1984-01-26 | Mitsubishi Paper Mills Ltd | Formation of image |
JPS59177557A (en) | 1983-03-28 | 1984-10-08 | Fuji Photo Film Co Ltd | Silver halide color photosensitive material |
DE3406329A1 (en) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | PYRIDONE |
US4816454A (en) * | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
AU606808B2 (en) | 1988-06-29 | 1991-02-14 | Otsuka Pharmaceutical Factory, Inc. | Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same |
US5235786A (en) * | 1989-11-06 | 1993-08-17 | Mitsubishi Jukogyo Kabushiki Kaisha | Hourglass worm gear |
GB9012936D0 (en) | 1990-06-11 | 1990-08-01 | Fujisawa Pharmaceutical Co | Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
US5254715A (en) | 1990-11-07 | 1993-10-19 | Warner-Lambert Company | Aminosulfonyl carbamates |
US5319099A (en) | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
TW225528B (en) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
EP0656768A4 (en) | 1992-08-20 | 1996-03-06 | Lipomatrix Inc | Penile implant with triglyceride fill. |
DE4302702A1 (en) | 1993-02-01 | 1994-08-04 | Bayer Ag | Arylaminosulfonylureas |
CA2159344A1 (en) | 1993-03-30 | 1994-10-13 | Minoru Moriwaki | Cell adhesion inhibitor and thienotriazolodiazepine compound |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
NO932986L (en) | 1993-08-20 | 1995-02-21 | Leiv Sandvik | Headrest device |
DE4337847A1 (en) | 1993-11-05 | 1995-05-11 | Bayer Ag | Substituted phenylaminosulphonylureas |
WO1995015954A1 (en) | 1993-12-07 | 1995-06-15 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5ht1d antagonists |
DE4343831A1 (en) | 1993-12-22 | 1995-06-29 | Magyar Tudomanyos Akademia | New N-substd. N-acyloxy:methyl-N'-sulphonyl-urea cpds |
FR2715155B1 (en) | 1994-01-19 | 1996-07-26 | Mayoly Spindler | Monoamine oxidase B inhibitors and methods of preparing them. |
DE4414840A1 (en) | 1994-04-28 | 1995-11-02 | Bayer Ag | Substituted phenylaminosulfonylureas |
WO1995034540A1 (en) | 1994-06-15 | 1995-12-21 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators |
WO1996016046A2 (en) | 1994-11-24 | 1996-05-30 | F. Hoffmann-La Roche Ag | Novel benzyl pyrimidines |
US5494925A (en) * | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
MX9704777A (en) | 1994-12-22 | 1997-10-31 | Smithkline Beecham Plc | Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists. |
KR100423818B1 (en) | 1995-04-24 | 2004-07-05 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | Liquid crystal compounds and liquid crystal compositions containing them |
JPH09221476A (en) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | Medicinal composition |
GB9605945D0 (en) | 1996-03-21 | 1996-05-22 | Smithkline Beecham Plc | Novel compounds |
JPH107804A (en) | 1996-06-25 | 1998-01-13 | Japan Synthetic Rubber Co Ltd | Thermosetting resin composition |
GB9623833D0 (en) | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
EP0867435B1 (en) | 1997-03-27 | 2003-01-08 | Great Lakes Chemical (Europe) GmbH | 2-(2'Hydroxyphenyl) benzotriazoles and their use as light stabilizers for organic polymers |
PT1019040E (en) | 1997-05-23 | 2005-01-31 | Bayer Pharmaceuticals Corp | INHIBITION OF THE ACTIVITY OF P38-KINASE BY MEANS OF ARILUREIAS |
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6294573B1 (en) * | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
EP1017378B1 (en) | 1997-09-23 | 2002-12-11 | AstraZeneca AB | Amide derivatives for the treatment of diseases mediated by cytokines |
IT1295933B1 (en) | 1997-10-30 | 1999-05-28 | Great Lakes Chemical Italia | 2- (2'-HYDROXYPHENYL) BENZOTHRIAZOLS AND PROCEDURE FOR THEIR PREPARATION |
US6080763A (en) * | 1997-11-03 | 2000-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
WO1999032110A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
DE69834842T2 (en) | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | INHIBITION OF RAF-KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREA |
ATE529109T1 (en) | 1997-12-22 | 2011-11-15 | Bayer Healthcare Llc | INHIBITION OF P38 KINASE ACTIVITY BY SUBSTITUTED HETEROCYCLIC UREAS |
IL136767A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
JPH11209350A (en) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | Nitrogen-containing heterocyclic derivative and medicine containing the same |
ES2189079T3 (en) | 1998-04-24 | 2003-07-01 | Leuven K U Res & Dev | IMMUNOSUPPRESSING EFFECTS OF XANTINA DERIVATIVES 8-SUBSTITUTED. |
PT1077931E (en) | 1998-05-15 | 2005-03-31 | Astrazeneca Ab | BEZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES |
AU761983B2 (en) | 1998-07-08 | 2003-06-12 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation,their use and pharmaceutical preparations comprising them |
US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
AU753360B2 (en) | 1998-07-31 | 2002-10-17 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
JP3602343B2 (en) * | 1998-09-02 | 2004-12-15 | アルプス電気株式会社 | Display device |
JP2002525358A (en) | 1998-09-25 | 2002-08-13 | アストラゼネカ アクチボラグ | Benzamide derivatives and their use as cytokine inhibitors |
JP2002527419A (en) | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Pyrrole-2,5-diones as GSK-3 inhibitors |
AU2725000A (en) | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
PL350357A1 (en) * | 1999-03-12 | 2002-12-02 | Boehringer Ingelheim Pharma | Heterocyclic urea and related compounds useful as anti−inflammatory agents |
JP2000275886A (en) | 1999-03-23 | 2000-10-06 | Konica Corp | Electrophotographic photoreceptor and process cartridge and image forming device using the same |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
JP3972163B2 (en) | 1999-06-18 | 2007-09-05 | 株式会社大塚製薬工場 | Phosphonic acid diester derivatives |
BR0013551A (en) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inhibitors of cjun (jnk) n-terminal kinases and other protein kinases |
AR035016A1 (en) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST. |
JP4316787B2 (en) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | An ether or amide derivative, a process for producing the same, and a therapeutic agent for diabetes containing the same, |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
US6500628B1 (en) | 2000-05-25 | 2002-12-31 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor |
JP2004503534A (en) | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 1,2,4-Trisubstituted benzenes as inhibitors of 15-lipoxygenase |
EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US20030181411A1 (en) | 2002-03-20 | 2003-09-25 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
CZ20031230A3 (en) | 2000-10-05 | 2003-10-15 | Fujisawa Pharmaceutial Co., Ltd | Benzamide derivative and pharmaceutical preparation containing thereof |
WO2002060869A2 (en) | 2000-10-19 | 2002-08-08 | Smithkline Beecham Corporation | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
WO2002034727A2 (en) | 2000-10-27 | 2002-05-02 | Novartis Ag | Treatment of gastrointestinal stromal tumors |
EP1340749A4 (en) | 2000-11-17 | 2007-09-05 | Takeda Pharmaceutical | Isoxazole derivatives |
JP2002226464A (en) | 2001-01-30 | 2002-08-14 | Sumitomo Pharmaceut Co Ltd | Triaryl analogue and its use |
EP1362037A1 (en) * | 2001-02-15 | 2003-11-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents |
US20030165873A1 (en) | 2001-03-02 | 2003-09-04 | Come Jon H. | Three hybrid assay system |
AU2002318374A1 (en) | 2001-06-21 | 2003-01-08 | Baylor College Of Medicine | Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway |
EP1281399A3 (en) | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
CA2458029A1 (en) * | 2001-09-13 | 2003-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
EP1465854A4 (en) | 2001-12-19 | 2005-06-08 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
WO2003059373A2 (en) | 2002-01-16 | 2003-07-24 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
BR0308108A (en) | 2002-02-28 | 2004-12-07 | Hoffmann La Roche | Compounds; process for the preparation of compound; pharmaceutical composition comprising the same, use of compounds and method of treatment and prophylaxis of diseases and obesity |
US20030186221A1 (en) | 2002-04-02 | 2003-10-02 | Lockhart David J. | Phage display affinity filter and forward screen |
US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
AU2003240026A1 (en) * | 2002-06-15 | 2003-12-31 | Samsung Electronics Co., Ltd. | Method of driving a shift register, a shift register, a liquid crystal display device having the shift register |
US20040138216A1 (en) | 2002-12-23 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea |
US20080045531A1 (en) | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
KR100705617B1 (en) * | 2003-03-31 | 2007-04-11 | 비오이 하이디스 테크놀로지 주식회사 | Liquid crystal driving device |
WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US20080220497A1 (en) | 2003-12-24 | 2008-09-11 | Flynn Daniel L | Modulation of protein functionalities |
CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
US20080248487A1 (en) | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
US20080248548A1 (en) | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
-
2003
- 2003-12-24 US US10/746,460 patent/US7144911B2/en not_active Expired - Fee Related
- 2003-12-26 WO PCT/US2003/041449 patent/WO2004060306A2/en active Search and Examination
- 2003-12-26 EP EP03814980A patent/EP1590344A4/en not_active Withdrawn
- 2003-12-26 BR BR0317872-2A patent/BR0317872A/en not_active IP Right Cessation
- 2003-12-26 MX MXPA05007236A patent/MXPA05007236A/en unknown
- 2003-12-26 AU AU2003303641A patent/AU2003303641A1/en not_active Abandoned
- 2003-12-26 EP EP03808576A patent/EP1585734A4/en not_active Withdrawn
- 2003-12-26 CA CA002513627A patent/CA2513627A1/en not_active Abandoned
- 2003-12-26 WO PCT/US2003/041425 patent/WO2004060305A2/en active Application Filing
- 2003-12-26 JP JP2005508625A patent/JP2006514691A/en not_active Withdrawn
- 2003-12-30 TW TW092137451A patent/TW200427672A/en unknown
-
2006
- 2006-01-20 US US11/337,245 patent/US20080187978A1/en not_active Abandoned
- 2006-06-09 US US11/450,849 patent/US7737283B2/en not_active Expired - Fee Related
- 2006-06-09 US US11/450,851 patent/US20090137021A1/en not_active Abandoned
- 2006-06-09 US US11/450,842 patent/US20090105230A1/en not_active Abandoned
- 2006-06-09 US US11/450,852 patent/US20090069310A1/en not_active Abandoned
- 2006-06-09 US US11/450,850 patent/US7666895B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
US6441005B1 (en) * | 1999-07-28 | 2002-08-27 | Pharmacia & Upjohn Company | Oxazolidinone compounds and compositions, and methods of using the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP1590344A2 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589116B2 (en) | 2003-04-03 | 2009-09-15 | Merck & Co. Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
JP2006527230A (en) * | 2003-06-13 | 2006-11-30 | ノバルティス アクチエンゲゼルシャフト | 2-Aminopyrimidine derivatives as RAF kinase inhibitors |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US7741479B2 (en) | 2004-12-07 | 2010-06-22 | Locus Pharmaceuticals, Inc. | Urea inhibitors of MAP kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
JP2010506850A (en) * | 2006-10-11 | 2010-03-04 | デシフェラ ファーマシューティカルズ,エルエルシー | Kinase inhibitors useful for the treatment of chronic myeloproliferative disorders and other proliferative disorders |
US8586600B2 (en) | 2007-06-04 | 2013-11-19 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
EP2152079A4 (en) * | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Heterocyclic compounds and uses thereof |
EP2152079A1 (en) * | 2007-06-04 | 2010-02-17 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US9067929B2 (en) | 2007-06-04 | 2015-06-30 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
EP2166858A4 (en) * | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | Novel heterocycle compounds and uses thereof |
WO2009046784A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8415345B2 (en) | 2008-05-06 | 2013-04-09 | Glaxo SmithKline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8642759B2 (en) | 2008-05-06 | 2014-02-04 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
US10323022B2 (en) | 2011-05-13 | 2019-06-18 | Array Biopharma Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors |
US9562055B2 (en) | 2011-05-13 | 2017-02-07 | Array Biopharma Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors |
US9878997B2 (en) | 2011-05-13 | 2018-01-30 | Array Biopharma Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9896435B2 (en) | 2012-11-13 | 2018-02-20 | Array Biopharma Inc. | N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
US10351575B2 (en) | 2012-11-13 | 2019-07-16 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
US10889589B2 (en) | 2012-11-13 | 2021-01-12 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US10851080B2 (en) | 2012-11-13 | 2020-12-01 | Array Biopharma Inc. | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds |
US10835533B2 (en) | 2014-05-15 | 2020-11-17 | Array Biopharma Inc. | 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor |
US11254681B2 (en) | 2014-08-04 | 2022-02-22 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10689383B2 (en) | 2014-08-04 | 2020-06-23 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10683293B2 (en) | 2014-08-04 | 2020-06-16 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
CN108203450B (en) * | 2016-12-19 | 2020-05-19 | 南京工业大学 | Preparation method and application of amino phosphonate containing arylpyrazole compound |
CN108203450A (en) * | 2016-12-19 | 2018-06-26 | 南京工业大学 | A kind of preparation method and application of the compound of arylpyrazoles containing amido phosphonate |
US11266635B2 (en) | 2019-08-12 | 2022-03-08 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11576904B2 (en) | 2019-08-12 | 2023-02-14 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US10966966B2 (en) | 2019-08-12 | 2021-04-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11344536B1 (en) | 2019-08-12 | 2022-05-31 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11813251B2 (en) | 2019-08-12 | 2023-11-14 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11426390B2 (en) | 2019-08-12 | 2022-08-30 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11433056B1 (en) | 2019-08-12 | 2022-09-06 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11529336B2 (en) | 2019-08-12 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11534432B2 (en) | 2019-08-12 | 2022-12-27 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11612591B2 (en) | 2019-12-30 | 2023-03-28 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11850240B1 (en) | 2019-12-30 | 2023-12-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11918564B1 (en) | 2019-12-30 | 2024-03-05 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11185535B2 (en) | 2019-12-30 | 2021-11-30 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
US11911370B1 (en) | 2019-12-30 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11903933B2 (en) | 2019-12-30 | 2024-02-20 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11793795B2 (en) | 2019-12-30 | 2023-10-24 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11801237B2 (en) | 2019-12-30 | 2023-10-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
US11395818B2 (en) | 2019-12-30 | 2022-07-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11844788B1 (en) | 2019-12-30 | 2023-12-19 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11576903B2 (en) | 2019-12-30 | 2023-02-14 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
US11850241B1 (en) | 2019-12-30 | 2023-12-26 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
US11896585B2 (en) | 2019-12-30 | 2024-02-13 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Also Published As
Publication number | Publication date |
---|---|
CA2513627A1 (en) | 2004-07-22 |
US20090075986A1 (en) | 2009-03-19 |
AU2003303641A1 (en) | 2004-07-29 |
US7666895B2 (en) | 2010-02-23 |
EP1585734A2 (en) | 2005-10-19 |
US20090137021A1 (en) | 2009-05-28 |
EP1585734A4 (en) | 2007-09-19 |
BR0317872A (en) | 2005-12-06 |
US20090105230A1 (en) | 2009-04-23 |
US20080299639A1 (en) | 2008-12-04 |
WO2004060305A3 (en) | 2005-02-10 |
US7737283B2 (en) | 2010-06-15 |
WO2004060306A2 (en) | 2004-07-22 |
US20090069310A1 (en) | 2009-03-12 |
TW200427672A (en) | 2004-12-16 |
EP1590344A4 (en) | 2007-08-29 |
US20080187978A1 (en) | 2008-08-07 |
MXPA05007236A (en) | 2006-04-27 |
US7144911B2 (en) | 2006-12-05 |
JP2006514691A (en) | 2006-05-11 |
US20040180906A1 (en) | 2004-09-16 |
EP1590344A2 (en) | 2005-11-02 |
WO2004060306A3 (en) | 2005-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004060305A2 (en) | Anti-cancer medicaments | |
US7342037B2 (en) | Anti-inflammatory medicaments | |
US7279576B2 (en) | Anti-cancer medicaments | |
US20070191336A1 (en) | Anti-inflammatory medicaments | |
WO2006081034A2 (en) | Anti-inflammatory medicaments | |
US20080045531A1 (en) | Anti-inflammatory medicaments | |
KR20070053249A (en) | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide kcnq potassium channel modulators | |
AU2003303639A1 (en) | Anti-cancer medicaments | |
US20060004051A1 (en) | Compounds | |
ZA200505268B (en) | Anti-inflammatory medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2511840 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1433/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200505267 Country of ref document: ZA Ref document number: 2003303639 Country of ref document: AU Ref document number: 2005508623 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/007237 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003814980 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038B00488 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003814980 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317863 Country of ref document: BR |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 30/2004 UNDER (71) THE NAME SHOULD READ "DECIPHERA PHARMACEUTICALS, LLC" |